Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer

被引:34
|
作者
Ohuchi, Mayuko [1 ]
Sakamoto, Yasuo [1 ]
Tokunaga, Ryuma [1 ]
Kiyozumi, Yuki [1 ]
Nakamura, Kenichi [1 ]
Izumi, Daisuke [1 ]
Kosumi, Keisuke [1 ]
Harada, Kazuto [1 ]
Kurashige, Junji [1 ]
Iwatsuki, Masaaki [1 ]
Baba, Yoshifumi [1 ]
Miyamoto, Yuji [1 ]
Yoshida, Naoya [1 ]
Shono, Takashi [2 ]
Naoe, Hideaki [2 ]
Sasaki, Yutaka [2 ]
Baba, Hideo [1 ]
机构
[1] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto 8608556, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol & Hepatol, Kumamoto 8608556, Japan
关键词
enhancer of zeste homolog 2; p21; colorectal cancer; adenoma-carcinoma sequence; ZESTE HOMOLOG 2; HISTONE METHYLTRANSFERASE; PROSTATE-CANCER; BREAST-CANCER; CYCLIN D1; PROTEIN; PROLIFERATION; METHYLATION; PROMOTES; ENHANCER;
D O I
10.3892/ol.2018.9240
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The adenoma-carcinoma sequence, the sequential mutation and deletion of various genes by which colorectal cancer progresses, is a well-established and accepted concept of colorectal cancer carcinogenesis. Proteins of the polycomb repressive complex 2 (PRC2) function as transcriptional repressors by trimethylating histone H3 at lysine 27; the activity of this complex is essential for cell proliferation and differentiation. The histone methyltransferase enhancer of zeste homolog 2 (EZH2), an essential component of PRC2, is associated with the transcriptional repression of tumor suppressor genes. EZH2 expression has previously been reported to increase with the progression of pancreatic intraductal papillary mucinous neoplasm. Thus, we hypothesized that EZH2 expression also increases during the adenoma-carcinoma sequence of colorectal cancer. The present study investigated changes in EZH2 expression during the colorectal adenoma-carcinoma sequence. A total of 47 patients with colorectal adenoma, 20 patients with carcinoma in adenoma and 43 patients with colorectal carcinoma who underwent surgical or endoscopic resection were enrolled in this study. Non-cancerous tissue from the clinical specimens was also examined. The association between EZH2 expression, pathology and expression of tumor suppressor genes during colorectal carcinogenesis were analyzed. Each specimen was immunohistochemically stained for EZH2, proliferation marker protein Ki-67 (Ki-67), cyclin-dependent kinase inhibitor (CDKN) 1A (p21), CDKN1B (p27) and CDKN2A (p16). Total RNA was extracted from formalin-fixed paraffin-embedded blocks and reverse transcription-quantitative polymerase chain reaction analysis of these genes was performed. Ki-67 and EZH2 expression scores increased significantly during the progression of normal mucosa to adenoma and carcinoma (P=0.009), and EZH2 expression score was positively associated with Ki-67 expression score (P=0.02). Conversely, p21 mRNA and protein expression decreased significantly, whereas expression of p27 and p16 did not change significantly. During the carcinogenesis sequence from normal mucosa to adenoma and carcinoma, EZH2 expression increased and p21 expression decreased significantly. EZH2 may therefore contribute to the development of colorectal cancer from adenoma via suppression of p21.
引用
收藏
页码:5275 / 5281
页数:7
相关论文
共 50 条
  • [31] Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population
    Zhou, Xiaozhou
    Liu, Nan
    Zhang, Jingqi
    Ji, Huixiang
    Liu, Yuting
    Yang, Jin
    Chen, Zhiwen
    SCIENTIFIC REPORTS, 2018, 8
  • [32] Organoids Are Limited in Modeling the Colon Adenoma-Carcinoma Sequence
    Tokumaru, Yoshihisa
    Oshi, Masanori
    Patel, Ankit
    Tian, Wanqing
    Yan, Li
    Matsuhashi, Nobuhisa
    Futamura, Manabu
    Yoshida, Kazuhiro
    Takabe, Kazuaki
    CELLS, 2021, 10 (03) : 1 - 15
  • [33] Genome-wide expression profiling in colorectal cancer focusing on lncRNAs in the adenoma-carcinoma transition
    Alexandra Kalmár
    Zsófia Brigitta Nagy
    Orsolya Galamb
    István Csabai
    András Bodor
    Barnabás Wichmann
    Gábor Valcz
    Barbara Kinga Barták
    Zsolt Tulassay
    Peter Igaz
    Béla Molnár
    BMC Cancer, 19
  • [34] The role of EZH2 in overall survival of colorectal cancer: a meta-analysis
    Vilorio-Marques, Laura
    Martin, Vicente
    Diez-Tascon, Cristina
    Francisca Gonzalez-Sevilla, Maria
    Fernandez-Villa, Tania
    Honrado, Emiliano
    Davila-Batista, Veronica
    Molina, Antonio J.
    SCIENTIFIC REPORTS, 2017, 7
  • [35] EZH2: An Accomplice of Gastric Cancer
    Yu, Wuhan
    Liu, Ning
    Song, Xiaogang
    Chen, Lang
    Wang, Mancai
    Xiao, Guohui
    Li, Tengfei
    Wang, Zheyuan
    Zhang, Youcheng
    CANCERS, 2023, 15 (02)
  • [36] The noncanonical role of EZH2 in cancer
    Huang, Jinhua
    Gou, Hongwei
    Yao, Jia
    Yi, Kaining
    Jin, Zhigang
    Matsuoka, Masao
    Zhao, Tiejun
    CANCER SCIENCE, 2021, 112 (04) : 1376 - 1382
  • [37] Genome-wide expression profiling in colorectal cancer focusing on lncRNAs in the adenoma-carcinoma transition
    Kalmar, Alexandra
    Nagy, Zsofia Brigitta
    Galamb, Orsolya
    Csabai, Istvan
    Bodor, Andras
    Wichmann, Barnabas
    Valcz, Gabor
    Bartak, Barbara Kinga
    Tulassay, Zsolt
    Igaz, Peter
    Molnar, Bela
    BMC CANCER, 2019, 19 (01)
  • [38] Nuanced evaluation of adenoma-carcinoma sequence in colorectal carcinoma. What is the role of serrated adenomas?
    Munding, J.
    Tannapfel, A.
    GASTROENTEROLOGE, 2013, 8 (06): : 495 - 503
  • [39] Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
    Fluge, O.
    Gravdal, K.
    Carlsen, E.
    Vonen, B.
    Kjellevold, K.
    Refsum, S.
    Lilleng, R.
    Eide, T. J.
    Halvorsen, T. B.
    Tveit, K. M.
    Otte, A. P.
    Akslen, L. A.
    Dahl, O.
    BRITISH JOURNAL OF CANCER, 2009, 101 (08) : 1282 - 1289
  • [40] Silencing of MBD2 and EZH2 inhibits the proliferation of colorectal carcinoma cells by rescuing the expression of SFRP
    Xie, Yang
    Wang, Feng
    Yu, Jun
    Zhang, Jing
    Liu, Yuting
    Li, Mengying
    Qi, Jian
    ONCOLOGY REPORTS, 2021, 46 (06)